Search hospitals > Nebraska > Omaha

Nebraska Methodist Hospital

Claim this profile
Omaha, Nebraska 68114
Global Leader in Cancer
Global Leader in Recurrence
Conducts research for Adenocarcinoma
Conducts research for Ovarian Cancer
Conducts research for Lung Cancer
338 reported clinical trials
12 medical researchers
Photo of Nebraska Methodist Hospital in OmahaPhoto of Nebraska Methodist Hospital in OmahaPhoto of Nebraska Methodist Hospital in Omaha

Summary

Nebraska Methodist Hospital is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Ovarian Cancer, Lung Cancer and other specialties. Nebraska Methodist Hospital is involved with conducting 338 clinical trials across 435 conditions. There are 12 research doctors associated with this hospital, such as Ralph Hauke, MD, Brent Tierney, MD, Timothy Huyck, and Robert M. Langdon.

Area of expertise

1Cancer
Global Leader
Nebraska Methodist Hospital has run 141 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Recurrence
Global Leader
Nebraska Methodist Hospital has run 58 trials for Recurrence. Some of their research focus areas include:
Stage IV
Stage III
Stage I

Top PIs

Clinical Trials running at Nebraska Methodist Hospital

Breast Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Cancer
Lung Cancer
Bladder Carcinoma
Ovarian Cancer
Pancreatic Cancer
Renal Cell Carcinoma
Oral Squamous Cell Carcinoma
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Imlunestrant

for Early Breast Cancer

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

T-DM1 + Tucatinib

for Breast Cancer

This study is evaluating whether a combination of two drugs may help prevent breast cancer from coming back.
Recruiting1 award Phase 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Nebraska Methodist Hospital?
Nebraska Methodist Hospital is a medical facility located in Omaha, Nebraska. This center is recognized for care of Cancer, Recurrence, Adenocarcinoma, Ovarian Cancer, Lung Cancer and other specialties. Nebraska Methodist Hospital is involved with conducting 338 clinical trials across 435 conditions. There are 12 research doctors associated with this hospital, such as Ralph Hauke, MD, Brent Tierney, MD, Timothy Huyck, and Robert M. Langdon.
Where is Nebraska Methodist Hospital located?
Nebraska Methodist Hospital, situated at 8303 Dodge St., Omaha, Nebraska, is a 423-bed acute care facility. It employs over 2,000 full-time staff and has 400 physicians on active staff. The hospital specializes in cancer care, cardiology, emergency services, neurology, neurosurgery, and orthopedics.
Who should I call to ask about financial aid or insurance network?
### Nebraska Methodist Hospital Financial Assistance and Insurance Inquiries **Billing Department** - General Billing Questions: (214) 947-6300 or toll-free (866) 364-9344. - Financial Counseling: - Methodist Dallas Medical Center: (214) 947-3422 - Methodist Charlton Medical Center: (214) 947-5516 - Methodist Mansfield Medical Center: (682) 622-7004 - Methodist Richardson Medical Center: (469) 204-2120 - Methodist Midlothian Medical Center: (469) 846-6102 **Financial Assistance** - Methodist Health System: (402) 354-4230 or 888-485-4494. - Methodist Fremont Health: (402) 941-7224. **Insurance Inquiries** - Visit the Methodist Hospital Foundation's Family Crisis Connection page. **Obtaining Financial Assistance** - Contact the Financial Assistance Department for payment options for self-pay patients. Required documents include ID card, driver's license, and doctor's order with diagnosis. **Financial Assistance Policy** - For a copy of the policy or to download the application, contact the Financial Assistance Department. **HealthPartners Insurance Members** - Call the Know Your Cost team at 952-993-7672 or use the online tool for cost estimates.
What insurance does Nebraska Methodist Hospital accept?
Nebraska Methodist Hospital accepts a wide range of insurance plans, including: - **Commercial Plans:** Aetna, Cigna, Humana, United Healthcare, and more. - **Medicaid Plans:** In Dallas County (Molina Healthcare, Parkland Community Health Plan, Wellpoint), and in Tarrant County (Aetna, Cook Children's, Wellpoint). - **Medicare Plans:** Medicare Part A & B, AARP Medicare Complete, Aetna Medicare, Anthem Medicare Advantage, among others. - **Military Programs:** TRICARE (inpatient and outpatient care), Veterans Choice Program.
What awards or recognition has Nebraska Methodist Hospital received?
Nebraska Methodist Hospital, located in Omaha, NE, is renowned for its exceptional maternity care, having earned a high performing designation. The hospital is actively involved in a wide range of clinical trials, focusing on areas such as cancer, cardiology, pulmonology, and vascular and vein conditions, showcasing its dedication to medical research and enhancing patient care.